With the new five-year funding, patients across Australia with rare or less common cancers will be able to access the program through a network of eight cancer centers.
Clearbridge will refer its patients to Genome.One's GoExplore test for disease risk assessment and drug response prediction.
Australia's Garvan Institute is teaming up with startup E-Nome to explore how secure storage of personal genomic records could support medical research.
The Garvan Institute's Genome.One plans to expand to a network of general practitioners, the Australian Financial Review reports.
The two firms are offering a combined genetic disease risk and pharmacogenomic analysis that covers 49 conditions and about 220 medications.
A new Australian service offers whole-genome sequencing and a health assessment, the Sydney Morning Herald reports.
An Australian team has sequenced and mapped the genome of a prostate cancer tumor, as the Australian Financial Review reports.
The reference bank is a sub-project of the Sydney Genomics Collaborative, and will be one of the world's largest publicly available genome banks of older healthy individuals.
The company's Irys genome mapping technology provides researchers with a non-sequencing-based tool that is essential for studying structural variation.
A team from Radboud University in the Netherlands performed a new detailed and transparent cost analysis for sequencing based on both static costs, and factors that may differ from institution to institution.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.